CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.88B, above the global median of $1.15B
- FinancialsAltman Z-Score 3.01: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.88BUSDvs all stocks (USD)
Revenue (TTM)
79.21MUSDvs all stocks (USD)
Profit Margin
-181.74%vs Biotechnology peers
Beta
1.15xvs all stocks
52-Week Change
43.75%vs all stocks
Market Capitalization
1.88BUSDvs all stocks (USD)
Enterprise Value
1.69BUSDvs all stocks (USD)
Forward P/E
-8.74xvs Biotechnology peers
Price to Sales (TTM)
23.75xvs Biotechnology peers
Price to Book (MRQ)
2.00xvs Biotechnology peers
Enterprise to Revenue
21.38xvs Biotechnology peers
Enterprise to EBITDA
-8.99xvs Biotechnology peers
Profit Margin
-181.74%vs Biotechnology peers
Operating Margin
-691.75%vs Biotechnology peers
Return on Assets (TTM)
-9.99%vs Biotechnology peers
Return on Equity (TTM)
-14.68%vs Biotechnology peers
Revenue (TTM)
79.21MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.2640USDUpdated Jul 17, 2026Quarterly Revenue Growth
96.30%vs Biotechnology peers
Gross Profit (TTM)
-111.79MUSDvs all stocks (USD)
EBITDA (TTM)
-188.28MUSDvs all stocks (USD)
Net Income (TTM)
-143.96MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
96.34%vs Biotechnology peers
Operating Cash Flow (TTM)
-153.26MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-114.04MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 17, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
75.13MUSDFY2025 · Dec 31, 2025Operating Income
-203.21MUSDvs all stocks (USD)
Pre-tax Income
-177.59MUSDFY2025 · Dec 31, 2025Income Tax Expense
-31.18MUSDFY2025 · Dec 31, 2025Net Income
-146.41MUSDFY2025 · Dec 31, 2025EBIT
-203.21MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-174.39MUSDFY2025 · Dec 31, 2025Research & Development
186.83MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
83.23MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-13.89MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
28.33MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.4900USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.4900USDFY2025 · Dec 31, 2025Basic Shares Outstanding
298.71MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
298.71MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-146.41MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-134.75MUSDFY2025 · Dec 31, 2025Free Cash Flow
-177.52MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
155.25MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-146.41MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
28.82MUSDFY2025 · Dec 31, 2025Stock-based Compensation
55.79MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.20MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-55.62MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-18.53MUSDFY2025 · Dec 31, 2025Capital Expenditures
-42.77MUSDFY2025 · Dec 31, 2025Net Acquisitions
-7.14MUSDFY2025 · Dec 31, 2025Purchase of Investments
-453.14MUSDFY2025 · Dec 31, 2025Sale of Investments
506.07MUSDFY2025 · Dec 31, 2025Other Investing Activity
54.61MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
57.64MUSDFY2025 · Dec 31, 2025Other Financing Charges
14.08MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
14.08MUSDFY2025 · Dec 31, 2025Shares Outstanding
303.95MSharesUpdated Jul 17, 2026Float Shares
205.09MSharesUpdated Jul 17, 2026Shares Short
48.56MSharesUpdated Jul 17, 2026Short Ratio
6.28daysvs all stocks
Short % of Shares Outstanding
20.61%vs all stocks
% Held by Insiders
23.04%vs all stocks
% Held by Institutions
42.57%vs all stocks
Total Cash (MRQ)
504.73MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.65USDUpdated Jul 17, 2026Total Debt (MRQ)
140.18MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1494xvs Biotechnology peers
Current Ratio (MRQ)
14.05xvs Biotechnology peers
Book Value per Share (MRQ)
3.09USDUpdated Jul 17, 2026Total Assets
1.36BUSDvs all stocks (USD)
Total Current Assets
728.23MUSDFY2025 · Dec 31, 2025Total Liabilities
390.05MUSDFY2025 · Dec 31, 2025Total Non-current Assets
628.72MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
325.74MUSDFY2025 · Dec 31, 2025Total Current Liabilities
64.31MUSDFY2025 · Dec 31, 2025Cash
99.30MUSDFY2025 · Dec 31, 2025Cash Equivalents
29.30MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
128.51MUSDFY2025 · Dec 31, 2025Other Short-term Investments
405.31MUSDFY2025 · Dec 31, 2025Accounts Receivable
58.29MUSDFY2025 · Dec 31, 2025Inventory
6.34MUSDFY2025 · Dec 31, 2025Accounts Payable
25.23MUSDFY2025 · Dec 31, 2025Short-term Debt
5.82MUSDFY2025 · Dec 31, 2025Deferred Revenue
22.51MUSDFY2025 · Dec 31, 2025Long-term Debt
137.40MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
4.77MUSDFY2025 · Dec 31, 2025Common Stock (Book)
802.34MUSDFY2025 · Dec 31, 2025Retained Earnings
-29.48MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
966.90MUSDvs all stocks (USD)
52-Week Low
2.75USDUpdated Jul 17, 202652-Week High
8.44USDUpdated Jul 17, 202652-Week Change
43.75%vs all stocks
Beta
1.15xvs all stocks
50-Day MA
5.83USDUpdated Jul 17, 2026200-Day MA
4.48USDUpdated Jul 17, 2026Avg 10-Day Volume
6.49MSharesUpdated Jul 17, 2026Avg 30-Day Volume
7.25MSharesUpdated Jul 17, 2026Diluted EPS (TTM)
-0.4800USDUpdated Jul 17, 2026Other Income / Expense
-2.71MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.01: safe zoneNotable
Altman Z-Score: 3.01
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.88B, above the global median of $1.15BNotable
Market cap (USD): 1,881,112,420Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Vazyme Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hugel Inc.
Tier 1ProductionApproval-Gated PipelineRule
UFP Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Amylyx Pharmaceuticals, Inc. Common Stock
Tier 1ProductionApproval-Gated PipelineRule
Zenas BioPharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jafron Biomedical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yifan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guobang Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tyra Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
MeiraGTx Holdings plc
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Immunome Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Iovance Biotherapeutics, Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC